Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 2:4:e67302.
doi: 10.2196/67302.

AI-Driven Tacrolimus Dosing in Transplant Care: Cohort Study

Affiliations

AI-Driven Tacrolimus Dosing in Transplant Care: Cohort Study

Mingjia Huo et al. JMIR AI. .

Abstract

Background: Tacrolimus forms the backbone of immunosuppressive therapy in solid organ transplantation, requiring precise dosing due to its narrow therapeutic range. Maintaining therapeutic tacrolimus levels in the postoperative period is challenging due to diverse patient characteristics, donor organ factors, drug interactions, and evolving perioperative physiology.

Objective: The aim of this study is to design a machine learning model to predict the next-day tacrolimus trough concentrations (C0) and guide dosing to prevent persistent under- or overdosing.

Methods: We used retrospective data from 1597 adult recipients of kidney and liver transplants at UC San Diego Health to develop a long short-term memory (LSTM) model to predict next-day tacrolimus C0 in an inpatient setting. Predictors included transplant type, demographics, comorbidities, vital signs, laboratory parameters, ordered diet, and medications. Permutation feature importance was evaluated for the model. We further implemented a classification task to evaluate the model's ability to identify underdosing, therapeutic dosing, and overdosing. Finally, we generated next-day dose recommendations that would achieve tacrolimus C0 within the target ranges.

Results: The LSTM model provided a mean absolute error of 1.880 ng/mL when predicting next-day tacrolimus C0. Top predictive features included the recent tacrolimus C0, tacrolimus doses, transplant organ type, diet, and interactive drugs. When predicting underdosing, therapeutic dosing, and overdosing using a 3-class classification task, the model achieved a microaverage F1-score of 0.653. For dose recommendations, the best clinical outcomes were achieved when the actual total daily dose closely aligned with the model's recommended dose (within 3 mg).

Conclusions: Ours is one of the largest studies to apply artificial intelligence to tacrolimus dosing, and our LSTM model effectively predicts tacrolimus C0 and could potentially guide accurate dose recommendations. Further prospective studies are needed to evaluate the model's performance in real-world dose adjustments.

Keywords: clinical decision-making; machine learning; organ transplantation; personalized medicine; tacrolimus.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: SN is a cofounder of Clairyon Inc., a University of California San Diego start-up dedicated to the commercialization of artificial intelligence–driven solutions for clinical quality monitoring, reporting, and improvement. He is also a consultant at Powell and Mansfield Inc., a sleep-disordered breathing diagnostics company. All other authors declare no other conflicts of interest.

Figures

Figure 1.
Figure 1.. Long short-term memory (LSTM) model architecture with detailed feature representation. ALT: alanine aminotransferase; BUN: blood urea nitrogen; Temp: temperature.
Figure 2.
Figure 2.. Patient selection and data processing flowchart.
Figure 3.
Figure 3.. Association between the difference in actual and recommended daily doses (distance) and average reward (mean and SE).

References

    1. Lu Z, Bonate P, Keirns J. Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. Br J Clin Pharmacol. 2019 Aug;85(8):1692–1703. doi: 10.1111/bcp.13952. doi. Medline. - DOI - PMC - PubMed
    1. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015 Jul;98(1):19–24. doi: 10.1002/cpt.113. doi. Medline. - DOI - PMC - PubMed
    1. Beermann KJ, Ellis MJ, Sudan DL, Harris MT. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. Clin Transplant. 2014 Jul;28(7):762–767. doi: 10.1111/ctr.12376. doi. Medline. - DOI - PubMed
    1. Alcamo AM, Clark RSB, Au AK, et al. Factors associated with neurobehavioral complications in pediatric abdominal organ transplant recipients identified using computable composite definitions. Pediatr Crit Care Med. 2020 Sep;21(9):804–810. doi: 10.1097/PCC.0000000000002355. doi. Medline. - DOI - PMC - PubMed
    1. Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE. Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies. Transplantation. 2020 Apr;104(4):881–887. doi: 10.1097/TP.0000000000002913. doi. Medline. - DOI - PubMed

LinkOut - more resources